Nymox Pharmaceutical Corp. (NYMX) on Monday released positive new clinical trial data from responder analysis of its pooled multi-center U.S. Phase 2 studies of NX-1207, indicating durable early responder benefits from Nymox's innovative drug treatment for benign prostatic hyperplasia or BPH.
The study concerned patients who reported a 6 point or better improvement in BPH Symptom Score improvement within a month of treatment. At follow-up, that is 14 months on average post-treatment, proportionally there were over 4.3 times as many NX-1207 early responders who had maintained a 6 point or better improvement in symptom score and who did not require further BPH treatment of any kind as compared to placebo controls.
NX-1207 is a novel drug developed by Nymox which is in Phase 3 development for the treatment of BPH. The drug has successfully completed a series of blinded controlled multi-center U.S. clinical trials where it has been found to produce improvements that are about double that reported for currently approved BPH drugs. NX-1207 is administered by a urologist in an office procedure that takes only a few minutes and involves little or no pain or discomfort.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.